Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease
Marieta Theodorakopoulou, Maria Eleni Alexandrou, Afroditi Boutou, et al.
Clinical Kidney Journal (2021) Vol. 15, Iss. 3, pp. 397-406
Open Access | Times Cited: 11

Showing 11 citing articles:

Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection
Jessica M. Vanslambrouck, Jessica A. Neil, Rajeev Rudraraju, et al.
Journal of Virology (2024) Vol. 98, Iss. 3
Open Access | Times Cited: 7
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
Vasiliki Tsampasian, Natasha Corballis, Vassilios S. Vassiliou
Current Hypertension Reports (2022) Vol. 24, Iss. 10, pp. 425-433
Open Access | Times Cited: 19
Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial
Vicente Navarro‐López, Adriana Hernández-Belmonte, Maria Isabel Pérez Soto, et al.
Medicine in Microecology (2022) Vol. 14, pp. 100061-100061
Open Access | Times Cited: 15
Emerging drugs for the treatment of diabetic nephropathy
Yoon Kook Kim, Xinyuan Ning, Kashif M. Munir, et al.
Expert Opinion on Emerging Drugs (2022) Vol. 27, Iss. 4, pp. 417-430
Closed Access | Times Cited: 11
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
Rodolfo Pedro Rothlin, Facundo Pelorosso, Mariano Duarte, et al.
Pharmacology Research & Perspectives (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 5
Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications
Artemios Karagiannidis, Marieta Theodorakopoulou, Charles J. Ferro, et al.
Clinical Kidney Journal (2022) Vol. 16, Iss. 4, pp. 619-634
Open Access | Times Cited: 7
Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
Rumen Filev, Lionel Rostaing, Mila Lyubomirova, et al.
Medicine (2022) Vol. 101, Iss. 48, pp. e31988-e31988
Open Access | Times Cited: 3
The dynamics of hypertension and renal function in CKD and non-CKD patients affected with COVID-19 – final results of BIRCOV trial
Д.Д. Іванов, Antolii Gozhenko, Mariia Ivanova, et al.
European Journal of Clinical and Experimental Medicine (2023) Vol. 21, Iss. 2, pp. 230-238
Open Access | Times Cited: 1
Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
Sidar Çöpür, Asiye Kanbay, Mehmet Kanbay
Clinical Kidney Journal (2022) Vol. 15, Iss. 5, pp. 852-854
Open Access | Times Cited: 2
Angiotensin and COVID-19
Gaetano Alfano
Elsevier eBooks (2023), pp. 473-489
Closed Access
Page 1

Scroll to top